Skip to main content
SpringerLink
Log in

Prostate Cancer

  • Chapter
  • First Online:
Urology at a Glance

  • 2125 Accesses

Abstract

Prostate cancer is the second most common cancer in men worldwide [1]. In the USA alone, 239,000 men will be diagnosed with prostate cancer in 2013 and 30,000 will die of the disease. Overall, 1 in every 6 men in the USA will be diagnosed with prostate cancer during his lifetime, and over 2.6 million men are currently living with the diagnosis [2]. Well-established risk factors for the prostate cancer are increasing age, African ancestry, and family history in a first-degree relative.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15(1):3866–71.

    PubMed  PubMed Central  Google Scholar 

  2. SEER cancer statistics review, 1975–2010. http://seer.cancer.gov/csr/1975_2010/.

  3. Scosyrev E, Wu G, Mohile S, Messing EM. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer. 2012;118(23):5768–76.

    Article  PubMed  Google Scholar 

  4. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58–64.

    PubMed  CAS  Google Scholar 

  5. D’Amico A, Whittington R, Malkowicz SB, et al. BIochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.

    Article  PubMed  Google Scholar 

  6. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D’Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, et al. Prostate cancer, version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10(9):1081–7.

    PubMed  CAS  Google Scholar 

  7. Wang L, Akin O, Mazaheri Y, Ishill NM, Kuroiwa K, Zhang J, Hricak H. Are histopathological features of prostate cancer lesions associated with identification of extracapsular extension on magnetic resonance imaging? BJU Int. 2010;106(9):1303–8.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Briganti A, Abdollah F, Nini A, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Passoni NM, Salonia A, et al. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol. 2012;61(6):1132–8. doi:10.1016/j.eururo.2011.11.008.

    Article  PubMed  Google Scholar 

  9. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010;116(22):5226–34.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011;117(13):2883–91.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997;15(3):1013–21.

    PubMed  CAS  Google Scholar 

  12. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103–6.

    Article  PubMed  CAS  Google Scholar 

  13. Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 2012;61(5):1019–24.

    Article  PubMed  Google Scholar 

  14. Abern MR, Aronson WJ, Terris MK, Kane CJ, Presti Jr JC, Amling CL, Freedland SJ. Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate. 2013;73(4):409–17.

    Article  PubMed  Google Scholar 

  15. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203–13. doi:10.1056/NEJMoa1113162.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1(4):293–7.

    CAS  Google Scholar 

  17. Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol. 2013;31:2029–36.

    Article  PubMed  CAS  Google Scholar 

  18. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

    Article  PubMed  CAS  Google Scholar 

  19. Abern MR, Dude AM, Tsivian M, Coogan CL. The characteristics of bladder cancer after radiotherapy for prostate cancer. Urol Oncol. 2013;31:1628–34.

    Article  PubMed  Google Scholar 

  20. Levine GN, D’Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010;60(3):194–201.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Briganti A, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, Chun FK, Sun M, Graefen M, Abdollah F, et al. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol. 2013;63(4):693–701.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, Duke University Medical Center, DUMC 3707, Durham, NC, 27710, USA

    Michael R. Abern MD, Matvey Tsivian MD & Judd W. Moul MD

Authors
  1. Michael R. Abern MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matvey Tsivian MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Judd W. Moul MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael R. Abern MD .

Editor information

Editors and Affiliations

  1. Dept. of Urology and Urologic Oncology, Medical School of Hanover (MHH), Hannover, Germany

    Axel S. Merseburger

  2. Department of Urology and Urologic Oncol, Medical School of Hanover (MHH), Hannover, Germany

    Markus A. Kuczyk

  3. Division of Urologic Surgery, Duke University Medical Center, Durham, North Carolina, USA

    Judd W. Moul

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Abern, M.R., Tsivian, M., Moul, J.W. (2014). Prostate Cancer. In: Merseburger, A., Kuczyk, M., Moul, J. (eds) Urology at a Glance. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54859-8_40

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54859-8_40

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54858-1

  • Online ISBN: 978-3-642-54859-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation